Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1942)	1/4/2008 11:04:49 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

GENZ traded above its Oct 15 H of 76.90 but is now a little below that level.<g> bigcharts.marketwatch.com GENZ & BMRN announced yesterday a restructuring of their joint venture regarding Aldurazyme (laronidase), but the operational responsibilities for BMRN & GENZ will not significantly change. Instead of sharing all costs and profits equally,GENZ will record sales of Aldurazyme and will pay BMRN a tiered payment ranging from approximately 39.5 to 50% of worldwide sales. BMRN will receive all of the benefits from increased manufacturing efficiencies and GENZ will receive all of the benefits from increased commercialization efficiencies. GENZ Is also getting ready to make an all time H.<g> bigcharts.marketwatch.com Bernard